Central Lab Market Segmentation:
End-user Segment Analysis
The pharmaceutical companies segment is anticipated to hold the notable share in the global central lab market during the forecast period on account of the clinical studies of prevalent genetic illnesses such as sickle cell anemia, Parkinson's disease, and Alzheimer's disease. As per the data from World Health Organization, in the last 25 years, the prevalence of Parkinson’s disease (PD) has doubled, and more than 8.5 million people worldwide are anticipated to have PD in 2019.
Our in-depth analysis of the global central lab market includes the following segments:
|
By Service Type |
|
|
By End-User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of central lab is evaluated at USD 3.81 billion.
The global central lab market size exceeded USD 3.62 billion in 2025 and is set to expand at a CAGR of over 5.7%, surpassing USD 6.3 billion revenue by 2035.
North America’s central lab market will dominate over 40.6% share by 2035, driven by increased R&D spending and rising prevalence of chronic diseases.
Key players in the market include Laboratory Corporation of America Holdings (Labcorp), ICON Plc, Medpace, Inc., Eurofins Scientific (Ireland) Limited, LabConnect, Cerba Research NV, Frontage Laboratories, Inc., Lambda Therapeutic Research Limited, InVitro International (IVRO), Clinical Reference Laboratory, Inc.
